Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Longo

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Cancer Immunology, Immunotherapy : CII|August 2, 2024
Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependentVíctor Albarrán, Patricia Guerrero, Coral García de Quevedo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal CancerHans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2022
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatmentsAlfonso Cortés, José L Casado, Federico Longo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 25, 2018
Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registryAlberto Carmona-Bayonas, Paula Jiménez-Fonseca, Isabel Echavarria, et al.
The Oncologist|October 19, 2024
Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patientsPatricia Guerrero, Víctor Albarrán, Carlos González-Merino, et al.
Science Translational Medicine|October 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumorsIván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz, et al.
British Journal of Cancer|August 3, 2017
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer RegistryPaula Jiménez Fonseca, Alberto Carmona-Bayonas, Raquel Hernández, et al.
Therapeutic Advances in Medical Oncology|July 2, 2021
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registryPaula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, et al.
Thrombosis and Haemostasis|August 29, 2019
Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with CancerAlberto Carmona-Bayonas, Paula Jimenez-Fonseca, Marcelo Garrido, et al.
The Lancet. Oncology|August 31, 2016
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysisSebastian Moran, Anna Martínez-Cardús, Sergi Sayols, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Cancer Immunology, Immunotherapy : CII|August 2, 2024
Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependentVíctor Albarrán, Patricia Guerrero, Coral García de Quevedo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal CancerHans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2022
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatmentsAlfonso Cortés, José L Casado, Federico Longo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 25, 2018
Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registryAlberto Carmona-Bayonas, Paula Jiménez-Fonseca, Isabel Echavarria, et al.
The Oncologist|October 19, 2024
Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patientsPatricia Guerrero, Víctor Albarrán, Carlos González-Merino, et al.
Science Translational Medicine|October 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumorsIván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz, et al.
British Journal of Cancer|August 3, 2017
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer RegistryPaula Jiménez Fonseca, Alberto Carmona-Bayonas, Raquel Hernández, et al.
Therapeutic Advances in Medical Oncology|July 2, 2021
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registryPaula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, et al.
Thrombosis and Haemostasis|August 29, 2019
Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with CancerAlberto Carmona-Bayonas, Paula Jimenez-Fonseca, Marcelo Garrido, et al.
The Lancet. Oncology|August 31, 2016
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysisSebastian Moran, Anna Martínez-Cardús, Sergi Sayols, et al.
Pageof 7